A Randomized, Double-Blind, Placebo-Controlled Trial Protocol Using the Fuzhengxiaoliu Patch for the Management of Primary Liver Cancer Pain

被引:0
|
作者
Li, Siman [1 ]
Wang, Binding [1 ]
Deng, Jiayao [2 ]
Li, Haiyan [2 ]
Wu, Yong [3 ]
Fang, Yu [2 ]
Yan, Bohua [2 ]
Chen, Yu [2 ]
机构
[1] Chengdu Univ TCM, Sch Clin Med, Chengdu, Sichuan, Peoples R China
[2] Hosp Chengdu Univ Tradit Chinese Med, Chengdu, Sichuan, Peoples R China
[3] Chengdu Zhongxiang Pharmaceut Technol Co Ltd, Chengdu, Sichuan, Peoples R China
来源
JOURNAL OF PAIN RESEARCH | 2025年 / 18卷
关键词
primary liver cancer; traditional Chinese medicine; Chinese herb; cancer pain management; randomized controlled trial; MECHANISMS;
D O I
10.2147/JPR.S500305
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Objective: Chronic pain strongly affects the quality of life of patients with liver cancer pain. Safe and effective management of cancer- related pain is a worldwide challenge. Traditional Chinese medicine (TCM) has rich clinical experience in the treatment of cancer pain. The Fuzhengxiaoliu patch (FZXLP) is a compound TCM with the effects of detoxification and pain relief and has shown great efficacy in the treatment of patients with liver cancer, but high-quality clinical research that provides research-based evidence is lacking. We designed a randomized, double-blind, placebo-controlled trial to explore and evaluate the efficacy of FZXLP for the treatment of liver cancer pain. Methods: This is a prospective, randomized, double-blind, placebo-controlled trial. The trial will enrol 72 participants with primary liver cancer with cancer pain (damp-heat stagnation and toxin and blood stasis syndrome). The primary objective is to measure the reduction in pain using FZXLP in combination with tegafur, gimeracil and oteracil potassium capsule (S-1) compared to the placebo group with S-1. Pain will be measured by the number of opioids used, Chinese versions of the numerical rating scale (NRS), pain relief rate and number of breakthrough cases of cancer pain (BTcP). The secondary objectives include response evaluation criteria in solid tumors (RECIST), tumor markers, TCM syndrome scores, weight, functional assessment of cancer therapy-hepatobiliary (FACT-Hep) questionnaire scores, and self-rating anxiety scale scores. Adverse events (AEs) will be recorded throughout the study. Discussion: This study integrated TCM with clinical research to assess the efficacy and safety of the addition of FZXLP in the treatment of primary liver cancer pain. Trial registration: Chinese clinical trial registry, ChiCTR2300076951, Registered on October 25, 2023. https://www.chictr.org.cn/ showproj.html?proj=209608.
引用
收藏
页码:33 / 42
页数:10
相关论文
共 50 条
  • [41] Metformin for low back pain: Study protocol for a randomised, double-blind, placebo-controlled trial
    Lim, Yuan Z.
    Urquhart, Donna M.
    Wang, Yuanyuan
    Estee, Mahnuma Mahfuz
    Wluka, Anita E.
    Heritier, Stephane
    Cicuttini, Flavia M.
    OSTEOARTHRITIS AND CARTILAGE OPEN, 2025, 7 (01):
  • [42] Patient-controlled methylphenidate for cancer fatigue: A double-blind, randomized, placebo-controlled trial
    Bruera, E
    Valero, V
    Driver, L
    Shen, LR
    Willey, J
    Zhang, T
    Palmer, JL
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (13) : 2073 - 2078
  • [43] Efficacy and safety of berberine for dyslipidemia: study protocol for a randomized double-blind placebo-controlled trial
    Ying Zhao
    Yuan-Yuan Yang
    Bao-Lin Yang
    Ya-Wei Du
    Da-Wei Ren
    Hong-Mei Zhou
    Jing Wang
    Hui-Min Yang
    Yao-Xian Wang
    Ying-Ying Zhang
    Sheng-Xian Wu
    Trials, 22
  • [44] Denosumab for treating periprosthetic osteolysis; study protocol for a randomized, double-blind, placebo-controlled trial
    Olof Sköldenberg
    Agata Rysinska
    Thomas Eisler
    Mats Salemyr
    Henrik Bodén
    Olle Muren
    BMC Musculoskeletal Disorders, 17
  • [45] Efficacy and safety of berberine for dyslipidemia: study protocol for a randomized double-blind placebo-controlled trial
    Zhao, Ying
    Yang, Yuan-Yuan
    Yang, Bao-Lin
    Du, Ya-Wei
    Ren, Da-Wei
    Zhou, Hong-Mei
    Wang, Jing
    Yang, Hui-Min
    Wang, Yao-Xian
    Zhang, Ying-Ying
    Wu, Sheng-Xian
    TRIALS, 2021, 22 (01)
  • [46] Kratom and Pain Tolerance: A Randomized Placebo-Controlled, Double-Blind Study
    Vicknasingam, Balasingam
    Chooi, Weng Tink
    Rahim, Azlan Abdul
    Ramachandram, Dinesh
    Singh, Darshan
    Ramanathan, Surash
    Yusof, Nur Sabrina Mohd
    Zainal, Hadzliana
    Murugaiyah, Vikneswaran
    Gueorguieva, Ralitza
    Mansor, Sharif Mahsufi
    Chawarski, Marek C.
    YALE JOURNAL OF BIOLOGY AND MEDICINE, 2020, 93 (02): : 229 - 238
  • [47] Denosumab for treating periprosthetic osteolysis; study protocol for a randomized, double-blind, placebo-controlled trial
    Skoldenberg, Olof
    Rysinska, Agata
    Eisler, Thomas
    Salemyr, Mats
    Boden, Henrik
    Muren, Olle
    BMC MUSCULOSKELETAL DISORDERS, 2016, 17
  • [48] PENTOXIFYLLINE FOR TREATMENT OF CANCER ANOREXIA AND CACHEXIA - A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL
    GOLDBERG, RM
    LOPRINZI, CL
    MAILLIARD, JA
    OFALLON, JR
    KROOK, JE
    GHOSH, C
    HESTORFF, RD
    CHONG, SF
    REUTER, NF
    SHANAHAN, TG
    JOURNAL OF CLINICAL ONCOLOGY, 1995, 13 (11) : 2856 - 2859
  • [49] Melatonin in Patients with Cancer Receiving Chemotherapy: A Randomized, Double-blind, Placebo-controlled Trial
    Sookprasert, Aumkhae
    Johns, Nutjaree Pratheepawanit
    Phunmanee, Anakapong
    Pongthai, Parichart
    Cheawchanwattana, Areewan
    Johns, Jeff
    Konsil, Julraht
    Plaimee, Preeyaporn
    Porasuphatana, Supatra
    Jitpimolmard, Suthiphan
    ANTICANCER RESEARCH, 2014, 34 (12) : 7327 - 7337
  • [50] Chemoprevention of Nonmelanoma Skin Cancer With Celecoxib: A Randomized, Double-Blind, Placebo-Controlled Trial
    Elmets, Craig A.
    Viner, Jaye L.
    Pentland, Alice P.
    Cantrell, Wendy
    Lin, Hui-Yi
    Bailey, Howard
    Kang, Sewon
    Linden, Kenneth G.
    Heffernan, Michael
    Duvic, Madeleine
    Richmond, Ellen
    Elewski, Boni E.
    Umar, Asad
    Bell, Walter
    Gordon, Gary B.
    JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2010, 102 (24): : 1835 - 1844